Click to rate
April 2008
Study of RA Drug Candidate Begins
Posted 4/25/08
The first patient has received a new dug in a Phase I trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA). The trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087. Preclinical research suggests that SBI-087, a fully humanized CD20-directed small modular immunopharmaceutical, may have enhanced potency in B-cell depletion compared with rituximab.
Orencia Approved for JRA
The anti-TNF biologic response modifer abatabacept (Orencia) has been approved to be marketed for use in children with juvenile rheumatoid arthritis.
